Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.

Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1020-4. doi: 10.1167/iovs.08-2654. Epub 2008 Oct 24.

PMID:
18952925
2.

Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.

Jockovich ME, Bajenaru ML, Piña Y, Suarez F, Feuer W, Fini ME, Murray TG.

Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2476-82.

PMID:
17525173
3.

Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy.

Jockovich ME, Piña Y, Alegret A, Cebulla C, Feuer W, Murray TG.

Retina. 2008 Mar;28(3 Suppl):S81-6. doi: 10.1097/IAE.0b013e318150d6f0. Erratum in: Retina. 2009 Jan;29(1):127.

PMID:
18317352
4.

Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME.

Ophthalmic Res. 2009;41(3):160-9. doi: 10.1159/000209670. Epub 2009 Mar 26.

5.

Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2671-7. doi: 10.1167/iovs.09-4255. Epub 2010 Jan 6.

6.

Increased hypoxia following vessel targeting in a murine model of retinoblastoma.

Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. doi: 10.1167/iovs.09-3702. Epub 2009 Jul 2.

PMID:
19578014
7.

Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.

Jockovich ME, Suarez F, Alegret A, Piña Y, Hayden B, Cebulla C, Feuer W, Murray TG.

Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5371-6.

PMID:
18055783
8.

Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.

Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME.

Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27.

9.

Higher vessel densities in retinoblastoma with local invasive growth and metastasis.

Rössler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schüler A, Bornfeld N, Schilling H.

Am J Pathol. 2004 Feb;164(2):391-4.

10.

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T.

Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.

11.

Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2.

Garcia JR, Gombos DS, Prospero CM, Ganapathy A, Penland RL, Chévez-Barrios P.

Arch Pathol Lab Med. 2015 Dec;139(12):1531-8. doi: 10.5858/arpa.2014-0262-OA.

PMID:
26619025
12.

Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.

Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH.

Arch Ophthalmol. 2008 Jul;126(7):953-8. doi: 10.1001/archopht.126.7.953.

PMID:
18625942
13.

Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells.

Wadhwa L, Bond WS, Perlaky L, Overbeek PA, Hurwitz MY, Chévez-Barrios P, Hurwitz RL.

Invest Ophthalmol Vis Sci. 2012 Jun 8;53(7):3454-62. doi: 10.1167/iovs.12-9549.

14.

The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties.

Pajovic S, Corson TW, Spencer C, Dimaras H, Orlic-Milacic M, Marchong MN, To KH, Thériault B, Auspitz M, Gallie BL.

Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7618-24. doi: 10.1167/iovs.11-7989.

15.

Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Schefler AC, Murray TG.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5359-68. doi: 10.1167/iovs.10-6321.

16.

Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma.

Escalona-Benz E, Jockovich ME, Murray TG, Hayden B, Hernandez E, Feuer W, Windle JJ.

Invest Ophthalmol Vis Sci. 2005 Jan;46(1):8-11.

PMID:
15623747
17.

[Relationship between vasculogenic mimicry and clinical pathological characters in retinoblastoma].

Niu YJ, Liu FL, Yang Y, Yuan CY.

Zhonghua Yan Ke Za Zhi. 2009 Apr;45(4):318-22. Chinese.

PMID:
19575963
18.

Basic fibroblast growth factor impact on retinoblastoma progression and survival.

Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, Murray TG.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5215-21. doi: 10.1167/iovs.07-1668. Epub 2008 Jul 9.

19.

[A new orthotopic retinoblastoma model expressing green fluorescent protein].

Wang XL, Xu P, Wang F, Zhao XF, Xue YH, Huang Q.

Zhonghua Yan Ke Za Zhi. 2004 Apr;40(4):225-8. Chinese.

PMID:
15268827
20.

Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.

Khan M, Walters LL, Li Q, Thomas DG, Miller JM, Zhang Q, Sciallis AP, Liu Y, Dlouhy BJ, Fort PE, Archer SM, Demirci H, Dou Y, Rao RC.

Lab Invest. 2015 Nov;95(11):1278-90. doi: 10.1038/labinvest.2015.104. Epub 2015 Aug 17.

Supplemental Content

Support Center